During the past decade, Chiba cancer center conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 4 clinical trials were completed, i.e. on average, 22.2% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 2 clinical trials were completed. i.e. 14.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chiba cancer center" #1 sponsor was "Amgen" with 4 trials, followed by "Haruhiko Fukuda" with 4 trials sponsored, "Pfizer" with 4 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored and "Merck Sharp & Dohme LLC" with 3 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chiba cancer center" #1 collaborator was "Ministry of Health, Labour and Welfare, Japan" with 5 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "ADIR, a Servier Group company" with 1 trials as a collaborator and "Astellas Pharma Inc" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Chiba cancer center" are "Breast Neoplasms" (3 trials), "Gastric Cancer" (3 trials), "Prostatic Neoplasms" (3 trials), "Breast Cancer" (2 trials) and "Gastroesophageal Junction Adenocarcinoma" (2 trials). Many other conditions were trialed in "Chiba cancer center" in a lesser frequency.

Most popular intervention types in "Chiba cancer center" are "Drug" (23 trials), "Biological" (5 trials), "Other" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Docetaxel" (4 trials), "Capecitabine" (3 trials), "Oxaliplatin" (3 trials) and "Pembrolizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Chiba cancer center" are 19 trials for "All" genders, 5 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Chiba cancer center". undefined are not yet recruiting, 6 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Chiba cancer center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Chiba cancer center, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".